Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Endocrine therapy is the mainstay of treatment in HR+/HER2- breast cancers, which represent about 70% of all breast cancers. Neoadjuvant therapy has been developed since the 1990s to address several issues, including breast-conserving surgery (BCS) and improvement of survival rates. For a long time,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/902 |
| _version_ | 1797395781378899968 |
|---|---|
| author | Florence Lerebours Luc Cabel Jean-Yves Pierga |
| author_facet | Florence Lerebours Luc Cabel Jean-Yves Pierga |
| author_sort | Florence Lerebours |
| collection | DOAJ |
| description | Endocrine therapy is the mainstay of treatment in HR+/HER2- breast cancers, which represent about 70% of all breast cancers. Neoadjuvant therapy has been developed since the 1990s to address several issues, including breast-conserving surgery (BCS) and improvement of survival rates. For a long time, neoadjuvant endocrine therapy (NET) was confined to frail patients in order to improve surgery outcome. Since the 2000s, NET now plays a central role as a research tool for predictive endocrine sensitivity biomarkers and targeted therapies. One of the major issues in early HR+/HER2- breast cancer is to identify patients in whom chemotherapy can be safely withheld. In vivo assessment of response to NET might be the best treatment strategy to address this issue. |
| first_indexed | 2024-03-09T00:39:32Z |
| format | Article |
| id | doaj.art-7327dcfc4268415495e979c46cfdad5b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T00:39:32Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7327dcfc4268415495e979c46cfdad5b2023-12-11T17:53:47ZengMDPI AGCancers2072-66942021-02-0113490210.3390/cancers13040902Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the ArtFlorence Lerebours0Luc Cabel1Jean-Yves Pierga2Medical Oncology Department, Institut Curie, 92210 Saint-Cloud, FranceMedical Oncology Department, Institut Curie, 92210 Saint-Cloud, FranceMedical Oncology Department, Institut Curie, 92210 Saint-Cloud, FranceEndocrine therapy is the mainstay of treatment in HR+/HER2- breast cancers, which represent about 70% of all breast cancers. Neoadjuvant therapy has been developed since the 1990s to address several issues, including breast-conserving surgery (BCS) and improvement of survival rates. For a long time, neoadjuvant endocrine therapy (NET) was confined to frail patients in order to improve surgery outcome. Since the 2000s, NET now plays a central role as a research tool for predictive endocrine sensitivity biomarkers and targeted therapies. One of the major issues in early HR+/HER2- breast cancer is to identify patients in whom chemotherapy can be safely withheld. In vivo assessment of response to NET might be the best treatment strategy to address this issue.https://www.mdpi.com/2072-6694/13/4/902breast cancerneoadjuvantendocrine therapyprognosis |
| spellingShingle | Florence Lerebours Luc Cabel Jean-Yves Pierga Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art Cancers breast cancer neoadjuvant endocrine therapy prognosis |
| title | Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art |
| title_full | Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art |
| title_fullStr | Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art |
| title_full_unstemmed | Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art |
| title_short | Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art |
| title_sort | neoadjuvant endocrine therapy in breast cancer management state of the art |
| topic | breast cancer neoadjuvant endocrine therapy prognosis |
| url | https://www.mdpi.com/2072-6694/13/4/902 |
| work_keys_str_mv | AT florencelerebours neoadjuvantendocrinetherapyinbreastcancermanagementstateoftheart AT luccabel neoadjuvantendocrinetherapyinbreastcancermanagementstateoftheart AT jeanyvespierga neoadjuvantendocrinetherapyinbreastcancermanagementstateoftheart |